Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Expert faculty review and share their insights and perspectives on key findings in MDS and MPNs presented at the 2021 ASH Annual Meeting.

Share

Program Content

Activities

  • Hematology 2021: MDS/MPN
    Key Studies in Myelodysplastic Syndromes and Myeloproliferative Neoplasms: Independent Conference Coverage of the 2021 ASH Annual Meeting
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 11, 2022

    Expires: May 10, 2023

Activities

Sabatolimab + HMA in MDS/AML
Phase Ib Study of Sabatolimab + Hypomethylating Agents for Very High–Risk/High-Risk MDS and Newly Diagnosed AML: Final Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2021

Expires: December 13, 2022

CPX-351 in HR MDS
Phase II Trial of CPX-351 as First-line Treatment in Patients With Higher-Risk MDS
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2021

Expires: December 13, 2022

FIGHT-203: Pemigatinib in MLN<sup><i>FGR1</i></sup>
FIGHT-203: Phase II Trial of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2021

Expires: December 13, 2022

IPSS-M Development
Development and Validation of a Molecular International Prognostic Scoring System (IPSS-M) for MDS Risk Stratification
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2021

Expires: December 14, 2022

Venetoclax/Azacitidine in MDS
Phase Ib Study: Venetoclax/Azacitidine in Treatment-Naive Higher-Risk MDS
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2021

Expires: December 14, 2022

Pelabresib in MF
MANIFEST: Pelabresib (CPI-0610) Monotherapy in Patients With Myelofibrosis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

Rusfertide in PV
Phase II Trial of Rusfertide (PTG-300) in Patients With Phlebotomy-Dependent Polycythemia Vera
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

HMA + Ven in MDS
Retrospective Analysis of Venetoclax + Hypomethylating Agents for Patients With Higher-Risk Myelodysplastic Syndromes
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

CPX-351 in Higher-Risk MDS
Pilot Study of CPX-351 in Transplant-Eligible Patients With Previously Untreated Higher-Risk MDS
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

PANTHER
PANTHER: Randomized Phase III Trial of First-line Pevonedistat + Azacitidine vs Azacitidine in Higher-Risk MDS/CMML or AML With 20% to 30% Marrow Blasts
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2021

Expires: December 19, 2022

MDS: LEN ± ELT
Phase II Trial of Lenalidomide and Eltrombopag for Low-Risk/Intermediate-Risk MDS
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Faculty

cover img faculity

Amy E. DeZern, MD, MHS

Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

cover img faculity

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation